329 related articles for article (PubMed ID: 35499745)
1. Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).
Smith PJ; McKeown SR; Patterson LH
IUBMB Life; 2023 Jan; 75(1):40-54. PubMed ID: 35499745
[TBL] [Abstract][Full Text] [Related]
2. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
Phillips RM
Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
[TBL] [Abstract][Full Text] [Related]
3. Exploring hypoxic biology to improve radiotherapy outcomes.
Li C; Wiseman L; Okoh E; Lind M; Roy R; Beavis AW; Pires IM
Expert Rev Mol Med; 2022 Apr; 24():e21. PubMed ID: 35586915
[TBL] [Abstract][Full Text] [Related]
4. The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.
Nesbitt H; Worthington J; Errington RJ; Patterson LH; Smith PJ; McKeown SR; McKenna DJ
Prostate; 2017 Nov; 77(15):1539-1547. PubMed ID: 28944496
[TBL] [Abstract][Full Text] [Related]
5. AQ4N: a new approach to hypoxia-activated cancer chemotherapy.
Patterson LH; McKeown SR
Br J Cancer; 2000 Dec; 83(12):1589-93. PubMed ID: 11104551
[TBL] [Abstract][Full Text] [Related]
6. Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach.
Yilmaz D; Tuzer M; Unlu MB
Math Biosci Eng; 2022 Aug; 19(11):10941-10962. PubMed ID: 36124576
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia Activated Prodrugs: Factors Influencing Design and Development.
Liang D; Miller GH; Tranmer GK
Curr Med Chem; 2015; 22(37):4313-25. PubMed ID: 26487420
[TBL] [Abstract][Full Text] [Related]
8. Precise gliomas therapy: Hypoxia-activated prodrugs sensitized by nano-photosensitizers.
Zhang H; Shi C; Han F; Li M; Ma H; Sui R; Long S; Sun W; Du J; Fan J; Piao H; Peng X
Biomaterials; 2022 Oct; 289():121770. PubMed ID: 36075142
[TBL] [Abstract][Full Text] [Related]
9. Prospects for hypoxia-based drug delivery platforms for the elimination of advanced metastatic tumors: From 3D modeling to clinical concepts.
Shahpouri M; Adili-Aghdam MA; Mahmudi H; Jaymand M; Amoozgar Z; Akbari M; Hamblin MR; Jahanban-Esfahlan R
J Control Release; 2023 Jan; 353():1002-1022. PubMed ID: 36516901
[TBL] [Abstract][Full Text] [Related]
10. In vitro radiosensitization of breast cancer with hypoxia-activated prodrugs.
Aiyappa-Maudsley R; Elsalem L; Ibrahim AIM; Pors K; Martin SG
J Cell Mol Med; 2022 Aug; 26(16):4577-4590. PubMed ID: 35841287
[TBL] [Abstract][Full Text] [Related]
11. Programmable therapeutic nanoscale covalent organic framework for photodynamic therapy and hypoxia-activated cascade chemotherapy.
He H; Du L; Xue H; Wu J; Shuai X
Acta Biomater; 2022 Sep; 149():297-306. PubMed ID: 35811069
[TBL] [Abstract][Full Text] [Related]
12. Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.
Su MX; Zhang LL; Huang ZJ; Shi JJ; Lu JJ
Curr Drug Targets; 2019; 20(6):668-678. PubMed ID: 30468124
[TBL] [Abstract][Full Text] [Related]
13. Role of hypoxia-activated prodrugs in combination with radiation therapy: An
Meaney C; Powathil GG; Yaromina A; Dubois LJ; Lambin P; Kohandel M
Math Biosci Eng; 2019 Jul; 16(6):6257-6273. PubMed ID: 31698561
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.
Patterson LH; McKeown SR; Ruparelia K; Double JA; Bibby MC; Cole S; Stratford IJ
Br J Cancer; 2000 Jun; 82(12):1984-90. PubMed ID: 10864207
[TBL] [Abstract][Full Text] [Related]
15. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.
Lindsay D; Garvey CM; Mumenthaler SM; Foo J
PLoS Comput Biol; 2016 Aug; 12(8):e1005077. PubMed ID: 27560187
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 - 2021.
Anduran E; Dubois LJ; Lambin P; Winum JY
Expert Opin Ther Pat; 2022 Jan; 32(1):1-12. PubMed ID: 34241566
[TBL] [Abstract][Full Text] [Related]
17. Targeting hypoxia in solid and haematological malignancies.
Harris B; Saleem S; Cook N; Searle E
J Exp Clin Cancer Res; 2022 Nov; 41(1):318. PubMed ID: 36320041
[TBL] [Abstract][Full Text] [Related]
18. The role of hypoxia-activated prodrugs in cancer therapy.
Denny WA
Lancet Oncol; 2000 Sep; 1(1):25-9. PubMed ID: 11905684
[TBL] [Abstract][Full Text] [Related]
19. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions.
Chen Z; Han F; Du Y; Shi H; Zhou W
Signal Transduct Target Ther; 2023 Feb; 8(1):70. PubMed ID: 36797231
[TBL] [Abstract][Full Text] [Related]
20. Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy.
Li Y; Zhao L; Li XF
Front Oncol; 2021; 11():700407. PubMed ID: 34395270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
